Gene nano-drug for activating tumor infiltration T cells as well as preparation method and application of gene nano-drug
Patent Information
- Application Number
- CN202411113813.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-14
- Publication Date
- 2024-11-26
AI Technical Summary
The prior art is difficult to activate tumor-infiltrating T cells efficiently and safely, resulting in insufficient anti-tumor immune effects and toxic side effects.
Using gene nanodrugs bound by plasmids and polymer nanoparticles, the plasmids expressing superantigens are delivered through nanoparticles composed of ionizable lipids and cationic lipids, and the tumor-specific promoter is used to ensure that gene expression is specifically activated in tumor cells. cells, reduce the impact on normal tissue.
It has achieved efficient activation of CD8+ and CD4+ T cells in tumor cells, enhanced tumor killing ability and immune response, reduced toxic side effects on normal tissues, and improved anti-tumor immune efficacy.
Smart Images

Figure CN119015403A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of medical technology, and in particular to a gene nano drug for activating tumor-infiltrating T cells, and a preparation method and application thereof. Background Art
[0002] Superantigens (SAg) are special antigens derived from bacteria or viruses. Unlike common antigens that need to be processed by antigen presenting cells and presented by the Major Histocompatibility Complex (MHC) before activating less than 0.01% of T cell clones, superantigens do not need to be processed intracellularly by antigen presenting cells. They directly bind to the outside of the antigen peptide binding groove of the MHC-II class molecule on the surface of the antigen presenting cell in the form of complete proteins, and then bind to the outside of the TCR variable β chain on the surface of the T cell. By forming an MHC-II-SAg-TCR ternary complex, it cross-links the MHC-II class molecule and the T cell antigen receptor (TCR), thereby efficiently and broadly activating CD8 + and CD4 + Only a very low concentration of 1 to 10 ng / mL is needed to non-specifically activate up to 20% of T cell clones, producing a very strong immune response.
[0003] While the injection of superantigens can produce a powerful anti-tumor effect in the body, it can also cause extremely strong toxic side effects. In 1999, Staphylococcus aureus enterotoxin was developed into aurein injection by Concord Biopharmaceutical Company and approved for the clinical treatment of various malignant tumors such as lung cancer and liver cancer. Its clinical results show that patients will experience side effects such as fever, local swelling and pain due to excessive expression of cytokines after injection. The toxic side effects can be reduced by intratumoral injection of superantigens. For example, Professor Sui Yanfang and others have proved that the growth of Hepa1-6 liver cancer can be effectively inhibited by intratumoral injection of adenovirus expression vectors of superantigens; JChluba and others have proved that intratumoral injection of polyethyleneimine-encapsulated superantigen expression plasmids can enhance the proliferation and killing function of T cells in melanoma. Therefore, the injection of superantigens can activate the anti-tumor effect of T cells, but the activation of T cells in normal tissues after injection will cause strong toxic side effects. Although intratumoral injection can reduce its toxic side effects, intratumoral injection is difficult to apply to metastatic tumors.
[0004] In addition, some researchers have linked tumor targeting groups to superantigens, using the targeting groups to guide superantigens to enrich in tumors, and selectively activate tumor-infiltrating T cells. Active Biotech and NeoTX have developed a tumor-targeted superantigen, Naptumomab, by coupling the Fab segment of an antibody targeting human carcinoembryonic antigen 5T4 with a superantigen to form a fusion protein. Through systemic administration, Naptumomab can be enriched in tumor tissues that highly express the 5T4 antigen, and efficiently activate tumor-infiltrating T cells to kill tumors. It has shown good tumor suppression effects and low toxic side effects in patients with non-small cell lung cancer, renal cell carcinoma, etc. However, the vast majority of tumors lack specific targeting groups, which not only makes it difficult to design targeted superantigens for different tumors, but even superantigens connected to targeting groups may still enter normal tissues to non-specifically activate T cells and produce toxic side effects, such as toxic shock syndrome reactions. The National Cancer Institute (NCI) and several academic institutions combined Staphylococcal Enterotoxin E (SEE) with the breast cancer-related antigen ErbB2 to form a new fusion protein SEE-ErbB2. This fusion protein can be administered by local injection to activate the immune response of T cells to breast cancer cells, induce the proliferation and activation of ErbB2-specific T cells, and thus enhance the immune system's response to breast cancer. Although ErbB has shown good efficacy in animal models, the superantigen can non-specifically activate a large number of T cells and cause strong immune responses, such as cytokine storms and immune-mediated toxic reactions; therefore, the project is currently at the preclinical stage, and its safety still needs to be further proven.
[0005] In summary, further breakthroughs are needed in how to use superantigens to efficiently, specifically, and safely activate tumor-infiltrating T cells and enhance T cell-mediated anti-tumor immune effects. Summary of the invention
[0006] The purpose of the present invention is to provide a gene nanomedicine for activating tumor-infiltrating T cells, and its preparation method and application, aiming to solve the technical problem of how to use superantigens to efficiently, specifically and safely activate tumor-infiltrating T cells and enhance the T cell-mediated anti-tumor immune effect in the prior art.
[0007] In order to achieve the above object, the technical solution of the embodiment of the present invention is:
[0008] The first aspect of the present invention provides a gene nanomedicine for activating tumor-infiltrating T cells, comprising: a plasmid and a polymer nanoparticle; the plasmid is a plasmid that can activate the expression of relevant genes in tumor-infiltrating T cells; the polymer nanoparticle is composed of ionizable lipids, cationic lipids and polymers, and can be used for the in vivo and in vitro encapsulation and delivery of nucleic acid drugs.
[0009] In combination with the first aspect, preferably, the plasmid is a plasmid expressing a superantigen SAg, and the superantigen SAg is at least one of a bacterial superantigen and a viral superantigen.
[0010] In combination with the first aspect, preferably, the bacterial superantigen is at least one of a superantigen produced by Staphylococcus aureus and a superantigen produced by Streptococcus pyogenes.
[0011] In combination with the first aspect, preferably, the superantigen produced by Staphylococcus aureus is at least one of Staphylococcus aureus enterotoxin and toxic shock syndrome toxin-1.
[0012] In combination with the first aspect, preferably, the Staphylococcus aureus enterotoxin is at least one of SEA, SEB, SEC, SED, SEE, SEG, SEH, SEI, SEJ, SEK, SEL, SEM, SEN, SEO, SEP, SEQ, SER, and SES.
[0013] In combination with the first aspect, preferably, the superantigen produced by Streptococcus pyogenes is at least one of SPEA, SPEB, SPEC, SPED, SPEE, SPEF, SPEG, SPEH, SPEI, SPEJ, SPEK, SPEL, and SPEM.
[0014] In combination with the first aspect, preferably, the plasmid is at least one of a human or mouse gene;
[0015] And / or, the promoter of the plasmid is a tumor-specific promoter; the tumor-specific promoter is at least one of a melanoma-specific tyrosinase Tyr promoter, a tumor-universal survivin Sur promoter, and a telomerase reverse transcriptase TERT promoter;
[0016] And / or, the terminator of the plasmid is bGH polyA.
[0017] In combination with the first aspect, preferably, the ionizable lipid is at least one of Dlin-MC3-DMA, SM-102, ALC-0315, Dlin-KC2-DMA, BHEM-DBA, BHEM-APMP, BHEM-EAA, and BHEM-AEA.
[0018] In combination with the first aspect, preferably, the cationic lipid is at least one of trimethyl-2,3-dioleyloxypropylammonium chloride, trimethyl-2,3-dioleyloxypropylammonium bromide, dimethyl-2-hydroxyethyl-2,3-dioleyloxypropylammonium bromide, dimethyl-2-hydroxyethyl-2,3-dioctadecyloxypropylammonium bromide, N-(2-spermine formyl)-N', N'-dioctadecylglycinamide, and 1,2-dioleoyl-3-succinyl-sn-glycerol choline ester.
[0019] In combination with the first aspect, preferably, the molar ratio of the cationic lipid to the ionizable lipid is 1:1-4;
[0020] And / or, the molar ratio of the cationic lipid to the nucleic acid is 1:1-4.
[0021] In combination with the first aspect, preferably, the average particle size of the polymer nanoparticles is 50nm-350nm;
[0022] and / or, the polymer in the polymer nanoparticles is at least one of polyethylene glycol-modified poly(glycolide-co-lactide) and poly(glycolide-co-lactide);
[0023] and / or, the polyethylene glycol-modified poly(glycolide-co-lactide) and the LA / GA ratio in the poly(glycolide-co-lactide) range from 95:5 to 50:50;
[0024] And / or, the molecular weight of the polyethylene glycol is in the range of 1000-10000 Daltons.
[0025] The second aspect of the present invention provides a method for preparing a gene nano drug for activating tumor-infiltrating T cells as described in any one of the first aspects, comprising the following steps:
[0026] The plasmids for activating tumor-infiltrating T cells were mixed with DEPC water to obtain an aqueous phase;
[0027] The ionizable lipid, the cationic lipid and ethanol are mixed to obtain a lipid ethanol solution; the polymer and the organic solvent are mixed to obtain a mixed solution, and the lipid ethanol solution and the mixed solution are mixed to obtain an oil phase;
[0028] Mixing the oil phase and the water phase to prepare an oil-in-water emulsion;
[0029] After the emulsion is allowed to stand at room temperature, the gene nano drug for activating tumor-infiltrating T cells is obtained.
[0030] The third aspect of the present invention provides a gene nanomedicine for activating tumor-infiltrating T cells as described in the first aspect or a gene nanomedicine for activating tumor-infiltrating T cells prepared by the method described in the second aspect, which is used to enhance the efficacy of T cell-mediated anti-tumor immunotherapy by non-specific broad-spectrum activation of tumor-infiltrating T cells.
[0031] The third aspect of the present invention provides a gene nanodrug for activating tumor-infiltrating T cells as described in the first aspect or a gene nanodrug for activating tumor-infiltrating T cells prepared by the method described in the second aspect, which is used in combination with immune checkpoint blockade therapy or CAR-T cell therapy to enhance the anti-tumor immune efficacy.
[0032] Compared with the prior art, the advantages or beneficial effects of the embodiments of the present invention include at least:
[0033] The gene nano drug for activating tumor-infiltrating T cells provided by the embodiment of the present invention uses cationic lipids and ionizable lipid-assisted polymer nanoparticles to deliver plasmids, forms water-in-oil nanoparticles for plasmid loading through hydrophilic-hydrophobic interactions, has excellent stability, and the polyethylene glycol shell can achieve long circulation in vivo. The size of the nanometer scale (about 100nm) can increase the enrichment of particles in tumors through the high permeability and retention effect (EPR effect) of solid tumors. Cationic lipids can assist nanoparticles in being taken up by cells, and ionizable lipids can assist nanoparticles in lysosomal escape. In addition, by adjusting the type, incorporation amount, and incorporation ratio of cationic lipids and ionizable lipids and polyethylene glycol-modified polyesters, a nanoparticle material library with different potentials and different PEG densities is established, and nanoparticles that efficiently deliver plasmids to targeted tumor tissues can be further screened. BRIEF DESCRIPTION OF THE DRAWINGS
[0034] Figure 1 The maps of the tumor-specific gene expression plasmids pTyr-SEA and pSur-SEA prepared in Example 1 of the present invention;
[0035] Figure 2 A schematic diagram of the preparation process of the gene nano drug for activating tumor-infiltrating T cells provided by the present invention;
[0036] Figure 3 iCLAN prepared in Example 2 of the present invention pTyr-SEA The particle size, potential and morphology characterization results diagram;
[0037] Figure 4 iCLAN prepared in Example 2 of the present invention pTyr-SEA 、iCLAN pSur-SEA The results of EGFP fluorescence flow cytometry of tumor-specific gene expression mediated by TNF-α;
[0038] Figure 5 iCLAN prepared in Example 2 of the present invention pTyr-SEA 、iCLAN pSur-SEA ELISA test results of inducing tumor cells to express SEA protein;
[0039] Figure 6 iCLAN prepared in Example 2 of the present invention pTyr-SEA Results of in vitro enhanced T cell infiltration and killing function test;
[0040] Figure 7 iCLAN prepared in Example 2 of the present invention pTyr-SEA 、iCLAN pSur-SEA Figure 1. Results of in vivo specific expression detection.
[0041] Figure 8 iCLAN prepared in Example 2 of the present invention pTyr-SEA Results of in vivo testing to inhibit melanoma growth and enhance T cell infiltration and activation;
[0042] Fig. 9 iCLAN prepared in Example 2 of the present invention pSur-SEA The results of the test show that the drug inhibits the growth of multiple tumors and enhances T cell infiltration and activation in vivo. DETAILED DESCRIPTION
[0043] In order to make the purpose, technical solutions and advantages of the present invention clearer, the present invention will be further described in detail below in conjunction with the accompanying drawings. The described embodiments should not be regarded as limiting the present invention. All other embodiments obtained by ordinary technicians in the field without making creative work are within the scope of protection of the present invention.
[0044] In the following description, reference is made to "some embodiments", which describe a subset of all possible embodiments, but it is understood that "some embodiments" may be the same subset or different subsets of all possible embodiments, and may be combined with each other without conflict. Unless otherwise defined, all technical and scientific terms used in the embodiments of the present invention have the same meaning as those commonly understood by those skilled in the art to which the embodiments of the present invention belong. The terms used in the embodiments of the present invention are only for the purpose of describing the embodiments of the present invention and are not intended to limit the present invention.
[0045] In the following description of this embodiment, the terms "include", "comprising", "having" and "containing" are all open terms, meaning including but not limited to.
[0046] It should be noted that all raw materials / reagents in the embodiments of the present invention can be purchased on the market or prepared according to conventional methods well known to those skilled in the art; the term "and / or" in the embodiments of the present invention is only used to describe the association relationship between associated objects, indicating that three relationships may exist, for example, A and / or B means the existence of A alone, B alone, and A and B at the same time, wherein A and B can be singular or plural, and the character " / " generally indicates that the associated objects before and after are in an "or" relationship.
[0047] In the following description of this embodiment, the term "at least one" refers to one or more, and "plurality" refers to two or more. "At least one of the following" or similar expressions refers to any combination of these items, including any combination of single items or plural items. For example, "at least one of a, b or c", or "at least one of a, b and c", can all represent: a, b, c, ab (i.e., a and b), ac, bc, or abc, where a, b, c can be single or multiple, respectively.
[0048] Those skilled in the art should understand that in the following description of the embodiments of the present invention, the order of serial numbers does not mean the order of execution, some or all of the steps can be executed in parallel or sequentially, and the execution order of each process should be determined by its function and internal logic, and should not constitute any limitation on the implementation process of the embodiments of the present invention.
[0049] The terms used in the embodiments of the present invention are only for the purpose of describing specific embodiments, and are not intended to limit the present invention. The singular forms "a", "an" and "the" used in the embodiments of the present invention and the appended claims are also intended to include plural forms, unless the context clearly indicates other meanings.
[0050] It will be appreciated by those skilled in the art that the numerical ranges in the embodiments of the present invention are to be understood as specifically disclosing each intermediate value between the upper and lower limits of the range. Each smaller range between the intermediate values in any stated value and stated range and any other stated value or intermediate value in the range is also included in the present invention. The upper and lower limits of these smaller ranges may be independently included or excluded in the range.
[0051] Unless otherwise specified, the technical / scientific terms used herein have the same meanings as those generally understood by those skilled in the art. Although the present invention only describes preferred methods and materials, any methods and materials similar or equivalent to those described herein may also be used in the embodiments or test cases of the present invention. All documents mentioned in this specification are generally incorporated by reference to disclose and describe methods and / or materials related to the documents. In the event of a conflict with any incorporated document, the content of the present invention shall prevail.
[0052] It should be noted that all raw materials and / or reagents in the examples of the present invention are purchased on the market or prepared according to conventional methods well known to those skilled in the art.
[0053] In the first aspect, an embodiment of the present invention provides a gene nanomedicine for activating tumor-infiltrating T cells, comprising: a plasmid and a polymer nanoparticle; the plasmid is a plasmid that can activate the expression of relevant genes in tumor-infiltrating T cells; the polymer nanoparticle is composed of ionizable lipids, cationic lipids and polymers, and can be used for the in vivo and in vitro encapsulation and delivery of nucleic acid drugs.
[0054] In a specific embodiment, the plasmid in the embodiment of the present invention is preferably a plasmid expressing a superantigen SAg, and the superantigen SAg is preferably one of a bacterial superantigen and a viral superantigen.
[0055] In a specific embodiment, the bacterial superantigen in the embodiment of the present invention is preferably one of the superantigens produced by Staphylococcus aureus and the superantigens produced by Streptococcus pyogenes.
[0056] In a specific embodiment, the superantigen produced by Staphylococcus aureus in the embodiment of the present invention is preferably one of Staphylococcus aureus enterotoxin and toxic shock syndrome toxin-1.
[0057] In a specific embodiment, the Staphylococcus aureus enterotoxin in the embodiment of the present invention is preferably one of SEA, SEB, SEC, SED, SEE, SEG, SEH, SEI, SEJ, SEK, SEL, SEM, SEN, SEO, SEP, SEQ, SER, and SES.
[0058] In a specific embodiment, the superantigen produced by Streptococcus pyogenes in the embodiment of the present invention is preferably one of SPEA, SPEB, SPEC, SPED, SPEE, SPEF, SPEG, SPEH, SPEI, SPEJ, SPEK, SPEL, and SPEM.
[0059] In a specific embodiment, the plasmid of the present invention is preferably at least one of human and mouse genes.
[0060] In a specific embodiment, the promoter of the plasmid of the embodiment of the present invention is preferably a tumor-specific promoter; the tumor-specific promoter is preferably one of the melanoma-specific tyrosinase Tyr promoter, the tumor-universal survivin Sur promoter and the telomerase reverse transcriptase TERT promoter.
[0061] It should be noted that tumor-specific promoters can selectively drive gene transcription and expression in tumor cells, but have no effect on other normal cells. Tyrosinase promoter can achieve melanoma-specific gene expression, and survivin promoter or telomerase reverse transcriptase promoter can achieve multiple tumor-specific gene expression.
[0062] In a specific embodiment, the terminator of the plasmid of the embodiment of the present invention is preferably bGH polyA.
[0063] In a specific embodiment, the ionizable lipid of the embodiment of the present invention is preferably one of Dlin-MC3-DMA, SM-102, ALC-0315, Dlin-KC2-DMA, BHEM-DBA, BHEM-APMP, BHEM-EAA, and BHEM-AEA.
[0064] It should be noted that these ionizable lipids can be electrically neutral at physiological pH when forming gene nanomedicines. After being endocytosed, they are positively charged in the acidic endosomal environment and interact with the negatively charged phospholipids on the endosomal membrane, thereby destroying the endosomal membrane and achieving endosomal escape, which helps to promote the release of delivered nucleic acid drugs and improve transfection efficiency.
[0065] In a specific embodiment, the cationic lipid of the embodiment of the present invention is preferably one of trimethyl-2,3-dioleyloxypropylammonium chloride (DOTMA), trimethyl-2,3-dioleyloxypropylammonium bromide (DOTAP), dimethyl-2-hydroxyethyl-2,3-dioleyloxypropylammonium bromide, dimethyl-2-hydroxyethyl-2,3-dioctadecyloxypropylammonium bromide, N-(2-spermine formyl)-N', N'-dioctadecylglycinamide (DOGS), and 1,2-dioleoyl-3-succinyl-sn-glycerocholine ester (DOSC); further, the cationic lipid is more preferably trimethyl-2,3-dioleyloxypropylammonium bromide (DOTAP).
[0066] It should be noted that these cationic lipids have the following effects when forming gene nano drugs: 1) They can form stable complexes with negatively charged nucleic acids (such as DNA or RNA), and this complex is easy to enter cells through the cell membrane, thereby improving the gene transfection of gene nano drugs. These cationic liposomes bind to nucleic acids through charge interactions, which can greatly compress the volume of nucleic acid molecules and promote their transfection and expression in cells. 2) After cationic liposome-mediated gene transfer, the liposomes will be degraded by enzymes in the cells, have no toxic side effects on cells, and show good biocompatibility. Compared with viral vectors, cationic liposomes have lower immunogenicity and toxicity as gene carriers, and can reduce immune responses and cytotoxicity. 3) The complex formed by cationic liposomes and nucleic acids can promote endocytosis of cells and effectively deliver nucleic acids to cells. In cells, the complex can release nucleic acids, allowing them to be transcribed and expressed in cells, thereby achieving the purpose of gene therapy. 4) Cationic liposomes such as DOTAP and DOTMA have hydrophobic tails and hydrophilic positively charged heads, which can form a stable interface between the aqueous phase and the organic phase, which is conducive to binding with nucleic acids and forming complexes. Cationic liposomes such as DOGS have specific chemical structures, such as a hydrophobic tail and a hydrophilic positively charged head, which give them unique biological properties and application potential.
[0067] In a specific embodiment, the molar ratio of the cationic lipid to the ionizable lipid in the embodiment of the present invention is preferably 1:1-4.
[0068] In a specific embodiment, the molar ratio of the cationic lipid to the nucleic acid in the embodiment of the present invention is preferably 1:1-4.
[0069] In a specific embodiment, the average particle size of the polymer nanoparticles of the embodiment of the present invention is preferably 50nm-350nm.
[0070] In a specific embodiment, the polymer in the polymer nanoparticles of the embodiment of the present invention is preferably one of polyethylene glycol-modified poly(glycolide-co-lactide) (PEG-b-PLGA) and poly(glycolide-co-lactide) (PLGA).
[0071] It should be noted that the polyethylene glycol-modified poly(glycolide-co-lactide) and the LA / GA ratio in the poly(glycolide-co-lactide) in the embodiments of the present invention are preferably in the range of 95:5-50:50.
[0072] In a specific embodiment, the molecular weight of the polyethylene glycol in the embodiment of the present invention is preferably in the range of 1000-10000 Daltons.
[0073] In a second aspect, an embodiment of the present invention provides a method for preparing the gene nano drug for activating tumor-infiltrating T cells according to the first aspect, the preparation method comprising:
[0074] S1: Mix the plasmid that activates tumor-infiltrating T cells with DEPC water to obtain an aqueous phase;
[0075] S2: mixing an ionizable lipid, a cationic lipid and ethanol to obtain a lipid ethanol solution; mixing a polymer and an organic solvent to obtain a mixed solution, and then mixing the lipid ethanol solution and the mixed solution to obtain an oil phase;
[0076] S3: mixing the oil phase and the water phase to prepare an oil-in-water emulsion;
[0077] S4: After the emulsion is allowed to stand at room temperature, the gene nanomedicine for activating tumor-infiltrating T cells is obtained.
[0078] In the preparation method provided by the present invention, there is no limitation on mixing in S1. For example, DEPC water can be first configured as a solution containing DEPC, and the solution containing DEPC can be an aqueous solution configured by DEPC and water, and then DEPC water is directly mixed with the plasmid that activates tumor-infiltrating T cells, and can be stirred to make it react evenly. The present invention preferably slowly adds the plasmid that activates tumor-infiltrating T cells to DEPC water under stirring to obtain an aqueous phase, so that the reaction is more uniform and the particle size of the formed aqueous phase particles is uniform. There is no special limitation on stirring in the present invention. For example, it can be magnetic stirring. Generally, in order to make the reaction more complete, the stirring reaction is continued for a period of time after the addition, which can be 0.3-2h. The rate of slow addition is preferably 6-50mL / min. The preferred environment of this step of the present invention is preferably room temperature to 80°C, that is, the temperature of mixing and reaction in step S1 can be room temperature to 80°C, and heating can be heated in a water bath.
[0079] In the preparation method provided by the present invention, in S2, ionizable lipids, cationic lipids and ethanol are mixed to obtain a lipid alcohol solution; a polymer and an organic solvent are mixed to obtain a mixed solution, and the lipid alcohol solution and the mixed solution are mixed to obtain an oil phase. The mixing of the present invention is not specifically limited. For example, the ionizable lipids and cationic lipids can be directly dissolved in ethanol at the same time to obtain a lipid ethanol solution; the ionizable lipids can also be first dissolved in ethanol to obtain a mixed solution, and then the cationic lipids are dissolved in the above-mentioned ionizable lipid ethanol solution to obtain a lipid ethanol solution; the cationic lipids can also be first dissolved in ethanol, and then the ionizable lipids are dissolved in the above-mentioned cationic lipid ethanol solution to obtain a lipid ethanol solution. In this mixing process, stirring can be performed, and heating and stirring can also be performed to make it react evenly. The present invention preferably first configures ethanol solutions of ionizable lipids and cationic lipids separately, and mixes the mixed solutions of the two to obtain a lipid ethanol solution, so that the reaction is more uniform and an oil phase is formed. There is no particular limitation on stirring in the present invention, for example, it can be magnetic stirring. Generally, in order to make the reaction more complete, stirring and reacting for a period of time after adding is continued, which can be 0.3-2h. The rate of slow addition is preferably 6-50mL / min. The preferred environment of this step of the present invention is preferably room temperature to 80°C, that is, the temperature of mixing and reacting in step S2 can be room temperature to 80°C, and heating can be heated in a water bath.
[0080] In the preparation method provided by the present invention, in S3, the oil phase and the water phase are mixed to prepare an oil-in-water emulsion. The present invention has no particular restrictions on mixing, for example, the oil phase and the water phase can be directly mixed. The method of the present invention preferably preparing the oil phase and the water phase into an oil-in-water emulsion can be any one of manual mixing, microfluidics and microchannel reaction methods.
[0081] In the preparation method provided by the present invention, after the emulsion is allowed to stand at room temperature in S4, the gene nano drug for activating tumor-infiltrating T cells is obtained. The present invention has no particular limitation on the standing time, and the standing time can be 10-60 minutes.
[0082] In a third aspect, an embodiment of the present invention provides a gene nanodrug for activating tumor-infiltrating T cells as described in the first aspect or a gene nanodrug for activating tumor-infiltrating T cells prepared by the method described in the second aspect, which is used to enhance the efficacy of T cell-mediated anti-tumor immunotherapy by non-specifically and broadly activating tumor-infiltrating T cells.
[0083] In a fourth aspect, an embodiment of the present invention provides a gene nanodrug for activating tumor-infiltrating T cells as described in the first aspect or a gene nanodrug for activating tumor-infiltrating T cells prepared by the method described in the second aspect, which is used in combination with immune checkpoint blockade therapy or CAR-T cell therapy to enhance the anti-tumor immune efficacy.
[0084] The gene nanomedicine for activating tumor-infiltrating T cells provided in the embodiment of the present invention specifically expresses superantigens in tumor cells, thereby promoting the activation of tumor-infiltrating CD8 + and CD4 + T cells are activated and kill tumors, and the expression of immune effector molecules such as cytokines in the tumor is increased, forming a significant cytokine concentration gradient between tumor tissue and peripheral tissue, prompting effector T cells to infiltrate tumor tissue and promote the anti-tumor effect of other adaptive immune cells, thereby enhancing the efficacy of T cell-mediated anti-tumor immunity, improving the tumor microenvironment, and effectively and specifically enhancing the effect of tumor immunotherapy.
[0085] The technical method of the present invention will be further described below in conjunction with specific embodiments.
[0086] Sources of raw materials used in the examples:
[0087] DOTAP and Dlin-MC3-DMA were purchased from Avituo Pharmaceutical Technology Co., Ltd.;
[0088] Polyester materials were purchased from Guangzhou Xinheng Biotechnology Co., Ltd.;
[0089] Dimethyl sulfoxide was purchased from Sinopharm Chemical Reagent Co., Ltd.;
[0090] B16-F10, MC38, Panc02, 4T1, C2C12, NIH-3T3, DC2.4, and RAW264.7 cells were purchased from ATCC;
[0091] Mouse primary skin cells, primary colon cells, primary pancreatic cells, and primary mammary cells were extracted from C57 BL / 6 mice;
[0092] Opti Reduced Serum Medium was purchased from Gibco;
[0093] CD3e, CD4, and CD8 sorting magnetic beads were purchased from Miltenyi Biotec;
[0094] BV510-anti mouse CD45, APC anti-mouse CD3, APC / Cy7 anti-mouse CD4, BV785anti-mouse CD8a, BV605 anti-mouse CD69, and PP / Cy5.5 anti-mouse Ki-67 flow cytometry antibodies were purchased from Biolegend;
[0095] Anti-SEA antibody was purchased from Thermo Fisher;
[0096] Anti-βactin antibody was purchased from Biosharp;
[0097] Annexin V-FITC / PI apoptosis kit was purchased from Elabscience;
[0098] Mouse His-tag, TNF-α, IFN-γ, and IL-2 ELISA kits were purchased from Nanjing GenScript Biotechnology Co., Ltd.;
[0099] Instrument models and companies used in the examples:
[0100] Nanoparticle size and Zeta potential instrument: model: Nano ZSE, Malvern, UK;
[0101] Field emission transmission electron microscope: model Talos F200x, Thermo Fisher, USA;
[0102] Analytical flow cytometer: model FACSCelesta, BD Company, USA;
[0103] Chemiluminescence imager: model: ChemiDoc MP, Bio-RAD, USA;
[0104] Tabletop refrigerated microcentrifuge: model Microfuge 20R, Beckman, USA;
[0105] Microplate reader: Model 800TS, Bio Tek, USA.
[0106] Example 1
[0107] Construction of superantigen SEA plasmid for activating tumor-infiltrating T cells
[0108] The superantigen SEA sequence comes from the NCBI gene database (Gene ID: 4555865). The superantigen SEA sequence and the gene sequence of the melanoma Tyr promoter or the tumor universal Sur promoter are constructed into a plasmid with pUC57 as the backbone by genetic engineering methods to obtain a tumor-specific superantigen (SEA) expression plasmid for melanoma or different types of tumors: denoted as pTyr-SEA and pSur-SEA. In addition, a series of plasmids carrying T2A, His-tag label, EGFP reporter gene, etc. are constructed using a similar method: pTyr-SAg-EGFP, pSur-SAg-EGFP, etc.
[0109] like Figure 1As shown, the main elements of the expression plasmid include Ori replication origin, Tyr or Sur promoter, SEA functional fragment, T2A, His-tag label, reporter gene EGFP, ampicillin resistance gene, and bGH polyA terminator.
[0110] Example 2
[0111] Preparation method of gene nanomedicine for activating tumor-infiltrating T cells and characterization of particle size, potential and morphology
[0112] Prepare ethanol solutions of Dlin-MC3-DMA and DOTAP respectively, and make the concentration of both solutions 20 mg / mL; prepare polyethylene glycol-modified poly(glycolide-co-lactide) (PEG 2k -b-PLGA 2k ) dimethyl sulfoxide solution to a concentration of 150 mg / mL. Add 10 μL of Dlin-MC3-DMA ethanol solution, 5 μL of DOTAP ethanol solution, 8 μL of PEG 2k -b-PLGA 2k Dimethyl sulfoxide solution and 5 μL of anhydrous ethanol were mixed by pipetting to obtain the oil phase.
[0113] 20 μg of pDNA was dissolved in enzyme-free DEPC water and the total volume was adjusted to 60 μL. The aqueous phase was obtained by pipetting and mixing.
[0114] The aqueous phase was added to the oil phase, pipetted for 15 seconds and then allowed to stand at room temperature for 10 minutes to obtain the nanomedicine. 4 mL of enzyme-free DEPC water was added and mixed by pipetting, and then transferred to a 100 kDa ultrafiltration tube and centrifuged at 3000 g for 5 minutes. The organic solvent was removed by centrifugation for 3 times to obtain the gene nanomedicine for activating tumor-infiltrating T cells, such as Figure 2 As shown, denoted as iCLAN pTyr-SEA or iCLAN pSur-SEA .
[0115] In order to verify the gene nanomedicine iCLAN prepared in Example 2 for activating tumor-infiltrating T cells pTyr-SEA Related performance of iCLAN pTyr-SEA The relevant biological properties of Figure 3 As shown, Figure 3 For example, CLAN pTyr-SEA Particle size, potential and morphology characterization results.
[0116] In the present invention, the prepared iCLAN pTyr-SEAIn the sample pool, the nanoparticle size and Zeta potential instrument were used to characterize the nanoparticles, and the hydration diameter of the nanoparticles, the corresponding nanoparticle size and Zeta potential distribution diagram were detected. Figure 3 As shown in A, the gene nanomedicine used to activate tumor-infiltrating T cells is nanoscale in size, has a uniform particle size distribution and is positively charged.
[0117] In the present invention, the prepared iCLAN pTyr-SEA Dilute 50 times with ultrapure water and disperse the particles by ultrasonic. Take 10 μL of the particle solution and drop it on the copper mesh. Let it stand at room temperature for 5-10 minutes, then use filter paper to absorb all the liquid. Then, under light-proof conditions, drop 10 μL of 2% phosphotungstic acid solution on the inner cover of a clean 60 mm culture dish. Use tweezers to gently clamp the edge of the copper mesh so that it contacts the droplet. After negative staining for 30 seconds, place it on the filter paper and wait for it to dry.
[0118] The morphology of nanomedicine was observed using a field emission transmission electron microscope at 200 kV. Figure 3 As shown in B, the gene nanomedicine for activating tumor-infiltrating T cells is a nanoscale spherical structure with a polyethylene glycol (PEG) shell.
[0119] Test Example 1
[0120] In vitro EGFP fluorescence detection of gene nanomedicine for activation of tumor-infiltrating T cells
[0121] In the present invention, 7×10 4 B16-F10, Panc02, MC38, 4T1 mouse tumor cells, DC2.4, NIH / 3T3, RAW264.7, C2C12 mouse normal cells, mouse epithelial, pancreatic, colon, and mammary primary cells were transfected when the cell confluence reached 70%. The old culture medium in the 24-well plate was discarded and replaced with a basic culture medium without dual antibodies. According to the preparation method in Example 2, 500 ng of iCLAN plasmid was added to each well. Control 、iCLAN pTyr-SEA-EGFP or iCLAN pSur-SEA-EGFP After gently shaking, place in an incubator and incubate for 6 hours. Replace with fresh complete medium. After 48 hours, detect EGFP fluorescence by flow cytometry. The test results are as follows Figure 4 As shown, Figure 4 As shown in A, use iCLAN pTyr-SEA-EGFP After transfection of B16-F10, Panc02, MC38, 4T1 mouse tumor cells and DC2.4, NIH / 3T3, RAW264.7, C2C12 mouse normal cells, flow cytometry detected that only B16-F10 cells expressed EGFP fluorescence 48 hours later, while other cells did not express it. Figure 4B shows that using iCLAN pSur-SEA-EGFP B16-F10, Panc02, MC38, 4T1 mouse tumor cells and mouse epithelial, pancreatic, colon, and mammary primary cells were transfected. 48 hours later, flow cytometry detected that B16-F10, Panc02, MC38, and 4T1 cells expressed EGFP fluorescence, while mouse primary cells did not.
[0122] Test Example 2
[0123] In vitro superantigen protein expression for gene nanomedicine to activate tumor-infiltrating T cells
[0124] In the present invention, 7×10 4 B16-F10, Panc02, MC38, 4T1 mouse tumor cells, DC2.4, NIH / 3T3, RAW264.7, C2C12 mouse normal cells, mouse epithelial, pancreatic, colon, and mammary primary cells were transfected when the cell confluence reached 70%. The old culture medium in the 24-well plate was discarded and replaced with a basic culture medium without dual antibodies. According to the preparation method in Example 2, 500 ng of iCLAN plasmid was added to each well. pTyr-SEA or iCLAN pSur-SEA After gently shaking, place in an incubator and incubate for 6 hours, then replace with Opti-MEM medium. After 72 hours, collect the supernatant, filter with a 0.22μm filter membrane to remove cell debris, and use a 3kda ultrafiltration tube to centrifuge at 3000g at 4℃ for 20 minutes. After centrifugation three times, a concentrated supernatant containing superantigen protein was obtained, and the concentration of supernatant protein was determined by BCA protein quantification method. The concentrated supernatant was quantitatively detected according to the mouse His-tag ELISA detection kit of GenScript. The results are as follows: Figure 5 As shown in A and 5B, iCLAN pTyr-SEA iCLAN only activates B16-F10 cells to efficiently express SEA protein pSur-SEA It can activate B16-F10, Panc02, MC38, and 4T1 cells to efficiently express His-tag protein, while the other cells do not express it.
[0125] Test Example 3
[0126] iCLAN, a genetic nanomedicine for activating tumor-infiltrating T cells pTyr-SEA Enhanced T cell activation and tumor killing in vitro
[0127] In the present invention, 7×10 4When the cell confluence reached 70%, the old culture medium in the 24-well plate was discarded and replaced with a basic culture medium without dual antibodies. According to the preparation method in Example 2, 500 ng of iCLAN plasmid was added to each well. Control or iCLAN pTyr-SEA After gently shaking, place in an incubator and incubate for 6 hours, then replace with Opti-MEM medium. After 72 hours, collect the supernatant, filter with a 0.22μm filter to remove cell debris, use a 3kda ultrafiltration tube, 3000g, 4℃, centrifuge for 20 minutes, and ultrafilter three times to obtain a concentrated supernatant containing superantigen protein. Extract spleen cells from C57 BL / 6 mice, incubate with the concentrated supernatant for 72 hours, centrifuge at a centrifugal speed of 2000rpm and a temperature of 4℃ for 3 minutes, and collect the cells and supernatant separately.
[0128] (I) Detection of T cell activation: Add αCD16 / 32 antibody to spleen cells, incubate at 4℃ for 15min for blocking, then add BV510 anti-mouse CD45, APC anti-mouse CD3, APC / Cy7 anti-mouse CD4, BV785 anti-mouse CD8a, BV605 anti-mouse CD69 flow cytometry antibody mixture, incubate at 4℃ for 1h for labeling, add 1x PBS after labeling to wash away unlabeled antibodies. Finally, use analytical flow cytometer to perform immune analysis on spleen cells. The results are as follows Figure 6 As shown in A, iCLAN pTyr-SEA Significantly enhanced T cell activation.
[0129] (II) Detection of cytokine secretion by T cells: Take the supernatant, remove the cell debris, and place it on ice for later use. Quantitatively detect the expression of TNF-α, IFN-γ and IL-2 in the supernatant using the mouse TNF-α, IFN-γ and IL-2 ELISA detection kits provided by GenScript. The results are as follows: Figure 6 As shown in B, iCLAN pTyr-SEA It can effectively increase the expression levels of TNF-α, IFN-γ and IL-2 in intratumoral T cells and enhance the killing of tumor cells.
[0130] (III) Detection of T cell killing effect: Count the B16-F10 cells and add 5×10 3 The cells were inoculated into a 96-well plate at a density of 10 cells / mL and cultured overnight at 37°C and 5% CO2. The spleen cells were collected after centrifugation and high-purity CD3 eMicroBeads magnetic beads were used to separate the CD3 eMicroBeads. + T cells were counted and 5 × 10 per well 4The cells were added to a 96-well plate at a density of 100 cells and incubated with B16-F10 cells for 48 hours. After incubation, the culture supernatant was discarded, the cells were washed once with 1x PBS, and then trypsin was digested and centrifuged at 500g for 5 minutes to collect the cell pellet. The cells were labeled according to the instructions of the cell apoptosis detection kit, and the cells were resuspended with 500μL BindingBuffer, and then 5μL Annexin V-FITC and 5μL PI were added and mixed; incubated at room temperature in the dark for 10 minutes, and the apoptosis level of tumor cells was detected by analytical flow cytometry. Figure 6 As shown in C, iCLAN pTyr-SEA It can significantly promote the apoptosis of B16-F10 cells.
[0131] Test Example 4
[0132] iCLAN, a genetic nanomedicine for activating tumor-infiltrating T cells pTyr-SEA 、iCLAN pSur-SEA In vitro specific detection
[0133] To verify iCLAN pTyr-SEA 、iCLAN pSur-SEA In vivo tumor-specific gene expression was performed. Twenty-four C57 BL / 6 mice with B16-F10 subcutaneous melanoma were randomly divided into four groups, with six mice in each group. 200 μL of PBS, SEA protein, iCLAN pTyr-SEA or iCLAN pSur-SEA The dose was 1 mg plasmid / kg body weight, administered once every 2 days for a total of 4 times. After the administration, the mice were sacrificed, and the tumor tissues and inguinal lymph nodes, heart, liver, spleen, lung and kidney tissues of the mice were isolated and obtained for subsequent detection.
[0134] (I) Detection of activation of tumor-infiltrating T cells; Parts of tumors and normal organs of mice were separated and used for flow cytometric analysis: 1 mg / mL collagenase IV, 100 μg / mL nuclease, and 100 μg / mL hyaluronidase were added to each tissue, and the tissue was placed in a 37°C incubator for 20 min for digestion. After grinding, red blood cell lysis, and 200-mesh nylon filtration, the cells were dispersed into single cells and finally detected using an analytical flow cytometer.
[0135] The results are as follows Figure 7 As shown in A and 7B, iCLAN pTyr-SEA 、iCLAN pSur-SEA Both can specifically induce tumor tissue to express SEA protein, while there is almost no expression in other organs.
[0136] (II) ELISA detection of SEA protein expression in each organ: The tumors and normal organs of another part of mice were used for ELISA detection: each tissue was quickly frozen in liquid nitrogen and then quickly ground, vortexed for 5 seconds immediately after adding RIPA lysis solution, placed on ice for 30 minutes, vortexed every 10 minutes, and then centrifuged at 12000g and 4℃ for 15 minutes to collect the supernatant protein. After measuring the protein concentration with the BCA protein quantification method, it was quantitatively detected according to the mouse His-tag ELISA detection kit of GenScript. The results are as follows Figure 7 C and 7D, iCLAN pTyr-SEA 、iCLAN pSur-SEA The SEA protein is only efficiently expressed in tumors and is hardly expressed in other organs.
[0137] Test Example 5
[0138] iCLAN, a genetic nanodrug that activates tumor-infiltrating T cells pTyr-SEA T cell infiltration and tumor growth inhibitory effects in melanoma
[0139] To verify iCLAN pTyr-SEA Thirty C57 BL / 6 mice bearing B16-F10 subcutaneous melanoma were randomly divided into five groups, with six mice in each group. The mice were injected into the tail vein with 200 μL of PBS, iCLAN Control 、iCLAN pTyr-SEA (0.5 mg plasmid / kg body weight), iCLAN pTyr-SEA (1 mg plasmid / kg body weight) or iCLAN pTyr-SEA (1 mg plasmid / kg body weight) combined with anti-PD-1 antibody (5 mg / kg body weight), once every 2 days, for a total of 4 times. During the entire treatment process, the tumor size was measured with a vernier caliper every 2 days. The tumor volume calculation formula is as follows: Volume (mm 3 )=0.5×length×width 2 After treatment, the tumor tissues of mice were isolated and weighed. Figure 8 As shown in A, iCLAN p Tyr-SEA Significantly inhibited the growth of mouse melanoma.
[0140] 1 mg / mL collagenase IV, 100 μg / mL nuclease, and 100 μg / mL hyaluronidase were added to each tissue, and the tissue was placed in a 37°C incubator and shaken for 20 minutes for digestion. After grinding, red blood cell lysis, and filtration through a 200-mesh nylon mesh, the tissue was dispersed into single cells. αCD16 / 32 antibody was added to the tissue single cells and incubated at 4°C for 15 minutes for blocking. Then, a mixture of BV510 anti-mouse CD45, APC anti-mouse CD3, APC / Cy7 anti-mouse CD4, BV785 anti-mouse CD8a, BV605anti-mouse CD69, and PP / Cy5.5 anti-mouse Ki-67 flow cytometry antibodies were added and incubated at 4°C for 1 hour for labeling. After labeling, 1x PBS was added to wash away the unlabeled antibodies. Finally, the tumor tissue was immunoanalyzed using an analytical flow cytometer. The results are shown in the following table. Figure 8 As shown in B, iCLAN pTyr-SEA It significantly enhanced the infiltration and proliferation of T cells in tumors and increased the number of activated cytotoxic T cells.
[0141] Test Example 6
[0142] iCLAN, a nanoparticle drug that activates tumor-infiltrating T cells pSur-SEA T cell infiltration and tumor growth inhibitory effects in various solid tumors
[0143] To verify iCLAN pSur-SEA In order to show the versatility of iCLAN in the treatment of various solid tumors, 24 C57 BL / 6 mice with B16-F10 subcutaneous melanoma and MC38 colorectal cancer were randomly divided into 4 groups with 6 mice in each group. The mice were injected into the tail vein with 200 μL of PBS, iCLAN and 200 μL of PBS. Control or iCLAN pSur-SEA The dose was 1 mg plasmid / kg body weight, administered once every 2 days for a total of 4 times. During the entire treatment process, the tumor size was measured with a vernier caliper every 2 days. Fig. 9 As shown in A and 9C, iCLAN pSur-SEA Significantly inhibited the growth of various types of tumors.
[0144] After the treatment, the mouse tumor tissue was isolated and processed into single cells according to the preparation method in Example 1, and the T cells infiltrating the tumor tissue were analyzed using an analytical flow cytometer. Fig. 9 B and 9D, iCLAN pSur-SEA Significantly increased the infiltration and activation of T cells in a variety of tumors.
[0145] The above is only a specific embodiment of the present invention, but the protection scope of the present invention is not limited thereto. Any person skilled in the art can easily think of changes or substitutions within the technical scope disclosed by the present invention, which should be included in the protection scope of the present invention. Therefore, the protection scope of the present invention should be based on the protection scope of the claims.
Claims
1. A gene nanomedicine for activating tumor-infiltrating T cells, characterized in that: include: Plasmid and polymer nanoparticles; the plasmid is a plasmid that can activate the expression of related genes in tumor-infiltrating T cells; the polymer nanoparticles are composed of ionizable lipids, cationic lipids and polymers, and can be used for in vivo and in vitro encapsulation and delivery of nucleic acid drugs.
2. The gene nanomedicine for activating tumor-infiltrating T cells according to claim 1, characterized in that: The plasmid is a plasmid for expressing a superantigen SAg, and the superantigen SAg is at least one of a bacterial superantigen and a viral superantigen.
3. The gene nanomedicine for activating tumor-infiltrating T cells according to claim 2, characterized in that: The bacterial superantigen is at least one of a superantigen produced by Staphylococcus aureus and a superantigen produced by Streptococcus pyogenes.
4. The gene nanomedicine for activating tumor-infiltrating T cells according to claim 3, characterized in that: The superantigen produced by Staphylococcus aureus is at least one of Staphylococcus aureus enterotoxin and toxic shock syndrome toxin-1.
5. The gene nanomedicine for activating tumor-infiltrating T cells according to claim 4, characterized in that: The Staphylococcus aureus enterotoxin is at least one of SEA, SEB, SEC, SED, SEE, SEG, SEH, SEI, SEJ, SEK, SEL, SEM, SEN, SEO, SEP, SEQ, SER, and SES.
6. The gene nanomedicine for activating tumor-infiltrating T cells according to claim 3, characterized in that: The superantigen produced by the Streptococcus pyogenes is at least one of SPEA, SPEB, SPEC, SPED, SPEE, SPEF, SPEG, SPEH, SPEI, SPEJ, SPEK, SPEL, and SPEM.
7. The gene nanomedicine for activating tumor-infiltrating T cells according to claim 1, characterized in that: The plasmid has at least one of human and mouse genes; And / or, the promoter of the plasmid is a tumor-specific promoter; the tumor-specific promoter is at least one of a melanoma-specific tyrosinase Tyr promoter, a tumor-universal survivin Sur promoter, and a telomerase reverse transcriptase TERT promoter; And / or, the terminator of the plasmid is bGH polyA.
8. The gene nanomedicine for activating tumor-infiltrating T cells according to claim 1, characterized in that: The ionizable lipid is at least one of Dlin-MC3-DMA, SM-102, ALC-0315, Dlin-KC2-DMA, BHEM-DBA, BHEM-APMP, BHEM-EAA, and BHEM-AEA.
9. The gene nanomedicine for activating tumor-infiltrating T cells according to claim 1, characterized in that: The cationic lipid is at least one of trimethyl-2,3-dioleyloxypropylammonium chloride, trimethyl-2,3-dioleyloxypropylammonium bromide, dimethyl-2-hydroxyethyl-2,3-dioleyloxypropylammonium bromide, dimethyl-2-hydroxyethyl-2,3-dioctadecyloxypropylammonium bromide, N-(2-spermine formyl)-N',N'-dioctadecylglycinamide, and 1,2-dioleoyl-3-succinyl-sn-glycerocholine ester.
10. The gene nanomedicine for activating tumor-infiltrating T cells according to claim 1, characterized in that: The molar ratio of the cationic lipid to the ionizable lipid is 1:1-4; And / or, the molar ratio of the cationic lipid to the nucleic acid is 1:1-4.
11. The gene nanomedicine for activating tumor-infiltrating T cells according to claim 1, characterized in that: The average particle size of the polymer nanoparticles is 50nm-350nm; and / or, the polymer in the polymer nanoparticles is at least one of polyethylene glycol-modified poly(glycolide-co-lactide) and poly(glycolide-co-lactide); and / or, the polyethylene glycol-modified poly(glycolide-co-lactide) and the LA / GA ratio in the poly(glycolide-co-lactide) range from 95:5 to 50:50; And / or, the molecular weight of the polyethylene glycol is in the range of 1000-10000 Daltons.
12. A method for preparing a gene nano drug for activating tumor-infiltrating T cells according to any one of claims 1 to 11, characterized in that: include: The plasmids for activating tumor-infiltrating T cells were mixed with DEPC water to obtain an aqueous phase; The ionizable lipid, the cationic lipid and ethanol are mixed to obtain a lipid ethanol solution; the polymer and the organic solvent are mixed to obtain a mixed solution, and the lipid ethanol solution and the mixed solution are mixed to obtain an oil phase; Mixing the oil phase and the water phase to prepare an oil-in-water emulsion; After the emulsion is allowed to stand at room temperature, the gene nano drug for activating tumor-infiltrating T cells is obtained.
13. A gene nanomedicine for activating tumor-infiltrating T cells according to any one of claims 1 to 12 or a gene nanomedicine for activating tumor-infiltrating T cells prepared by the method according to claim 11, which is used to enhance the efficacy of T cell-mediated anti-tumor immunotherapy by non-specific broad-spectrum activation of tumor-infiltrating T cells.
14. A gene nano drug for activating tumor-infiltrating T cells as described in any one of claims 1 to 12 or a gene nano drug for activating tumor-infiltrating T cells prepared by the method of claim 12 in combination with immune checkpoint blockade therapy or CAR-T cell therapy to enhance the anti-tumor immune efficacy.
